scholarly journals PMS7 Direct Treatment-Cost of Patients with Rheumatoid Arthritis in Medellin, Colombia

2011 ◽  
Vol 14 (7) ◽  
pp. A562
Author(s):  
N. Montoya ◽  
L. Gómez ◽  
M. Vélez ◽  
D. Rosselli
Keyword(s):  
Rheumatoid Arthritis ◽  
Treatment Cost ◽  
Direct Treatment ◽  
Direct Treatment Cost

scholarly journals UNSTABLE ANGINA

2010 ◽  
Vol 23 (10) ◽  
pp. 1276-1280
Author(s):  
Shazia Alam ◽  
Syed Baqir Syum Naqvi ◽  
Maqsood Ahmed ◽  
Syed Baqir Syum Naqvi
Keyword(s):  
Unstable Angina ◽  
Conservative Management ◽  
Treatment Cost ◽  
Tertiary Care ◽  
Cost Of Care ◽  
Total Direct Cost ◽  
Care Hospital ◽  
Direct Treatment ◽  
Direct Treatment Cost ◽  
The Cost

Objective: To determine the direct treatment cost of unstable angina (UA) withlow molecular weight heparin (LMWH) in conservative management. Study design: Prospectivestudy. Settings: Government cardiovascular hospital and private tertiary care hospital, Karachi.Study period: One year. Method: All 487 patients with either sex having cardiac history ofischemic heart disease, presenting chest pain diagnosed to have unstable angina admitted inhospital for 2-8 days were recruited and entered in study. The current prospective study wasdesigned to analyze the direct treatment cost of UA with LMWH. Data was collected throughproforma and results were analyzed by SPSS version 20. Results: Results were represented interms of percentages, frequencies and means of cost contribution of LMWH. All costs valuesconverted from Pakistani currency (PKR) into US dollars ($) as per exchange rate of 2014. Lessnumber of prescriptions found for fondaparinux (24.85%) than enoxaparin (70%). The estimatedmean of drug cost particularly observed in three treatment groups of patients who receivedenoxaparin, fondaparinux and dalteparin was $36, $ 15 and $ 47 correspondingly. Moreover,4 days total direct cost of enoxaparin and fondaparinux was $191, $ 84 and 6 days treatmentcosts $ 149 with dalteparin to treat a single case of UA. It has been found that fondaparinuxsignificantly lowers the cost of care in comparison to enoxaparin and dalteparin. Conclusion:Current analysis concluded that in the treatment of unstable angina, fondaparinux found to bea dominant strategy that simultaneously lowers the cost of care in conservative management.

scholarly journals Analysis of Direct Treatment Cost for Exacerbation of Chronic Obstructive Pulmonary Disease in E Hospital from October 2019 to March 2020

2020 ◽  
Vol 36 (2) ◽  
Author(s):  
Bui Thi Xuan ◽  
Ngo Tien Thanh ◽  
To Khanh Linh
Keyword(s):  
Chronic Obstructive Pulmonary Disease ◽  
Pulmonary Disease ◽  
Treatment Cost ◽  
Respir Crit ◽  
Chronic Obstructive ◽  
Obstructive Pulmonary Disease ◽  
Direct Treatment ◽  
Direct Treatment Cost ◽  
Exacerbation Of Copd ◽  
The Cost

This study analyzes the direct treatment cost for exacerbation of chronic obstructive pulmonary disease (COPD) at the Department of Pulmonology, E Hospital from October 2019 to March 2020. The study results show that the average direct treatment cost for exacerbation of COPD was VND 9,102,311.71; the highest cost was VND 36,304,614 and the lowest cost, VND 2,309,961. Among the direct treatment cost components, drug cost showed the highest proportion, followed by hospital bed, then surgical procedures, tests, diagnostic imaging, functional exploration, examination and medical supplies. The cost of antibiotics accounted for 57.76% of the drug cost. The average number of hospitalization days was 10.77, closely relating to the direct cost. Besides, age and comorbidity also affected the number of hospitalization days. The average health insurance support for each patient was up to 94.46% of the total treatment cost. The results also show that the cost of treatment in Vietnam is lower than some countries in the region and the proportions of the cost components presented in different studies in Vietnam are different. Keywords Direct cost, exacerbation of COPD, E hospital. [1] Ngo Quy Chau, Nguyen Lan Viet, Nguyen Dat Anh, Pham Quang Vinh, Internal Pathology, Medical Publishing House 1 (2018) 42-50 (in Vietnamese).[2] R.A. Pauwels, A.S. Buist, P.M.A. Calverley, C. R. Jenkins, S. Hurd Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 163 (2001) 1256–1276. https://doi.org/10.1164/ajrccm.163.5.2101039[3] https://www.chestnet.org/News/Press-Releases /2014/07/CDC-reports-36-billion-in-annual financial-cost-of-COPD-in-US (15/10/2019)[4] S.D. Sullivan, S.D. Ramsey, T.A. Lee, The economic burden of COPD. Chest 2000 Feb 117(2), 5S-9S.https://journal.chestnet.org/article/S0012-3692(15)52748-7/fulltext[5] Vanfleteren, E.G.W. Lowie, et al Clusters of comorbidities based on validated objective measurements and systemic inflammation in patients with chronic obstructive pulmonary disease American journal of respiratory and critical care medicine 187(7) (2013) 728-735. https://www.atsjournals.org/doi/full/10.1164/rccm.201209-1665oc [6] Doan Quynh Huong Analysis of direct costs of inpatient treatment for EPI in Respiratory Center of Bach Mai Hospital from 2013-2015, 2017 (in Vietnamese).[7] Vu Xuan Phu, Duong Viet Tuan, Nguyen Thu Ha et al., Inpatient treatment costs of patients with chronic obstructive pulmonary disease at central lung hospital, 2009, Journal of Practical Medicine 1 (2012) 51-53 (in Vietnamese).http://yhth.vn/chi-phi-dieu-tri-noi-tru-cua-benh-nhan-benh-phoi-tac-nghen-man-tinh-tai-benh-vien-phoi-trung-uong-nam-2009_t3254.aspx[8] C.S. Rand, M. Nides, M.K. Cowles, R.A. Wise, J. Connett, Long-term metered-dose inhaler adherence in a clinical trial. The lung health study research group. Am J Respir Crit Care Med, Aug 152(2) (1995) 580-8. https://doi.org/10.1164/ajrccm.152.2.7633711[9] Phan Thi Thanh Hoa, Clinical features, clinical and direct treatment costs of patients with chronic obstructive pulmonary disease at Respiratory Center - Bach Mai Hospital Graduation thesis general practitioner, Hanoi Medical University 2013 (in Vietnamese).  

scholarly journals The Economic impact of Lower Extremity Amputations in Diabetics. A retrospective study from A Tertiary Care Hospital of Faisalabad, Pakistan

2020 ◽  
Vol 1 (1) ◽  
pp. 18-22
Author(s):  
Muhammad Labeeq ◽  
Muhammad Ahsan Tariq ◽  
Samra Atta Tung ◽  
Muhammad Asfand Yar ◽  
Waleed Rehman ◽  
...  
Keyword(s):  
Lower Extremity ◽  
Economic Burden ◽  
Diabetic Foot ◽  
Treatment Cost ◽  
Tertiary Care Hospital ◽  
Tertiary Care ◽  
Care Hospital ◽  
Direct Treatment ◽  
Direct Treatment Cost ◽  
The Mean

Background: Among the various complications of diabetes, lower-extremity amputation due to diabetic foot is a common problem. In Pakistan, 6-7% of patients with diabetes suffer from diabetic foot ulceration. Objectives: Our primary objective was to explore the frequency of diabetic foot amputations, and the secondary objective was to calculate the economic burden of these preventable surgeries on the health budget of the provincial government. Materials & Methods: It was a retrospective cross-sectional observational study conducted after obtaining approval from the Ethical Review Committee of Allied hospital, Faisalabad Medical University. The data of diabetic foot patients who underwent amputations between July 2017 and December 2017 were retrieved from three Surgical Units (I, II & III), using a purposive sampling technique. All amputations carried out for reasons other than diabetic foot were excluded. The direct medical cost of one diabetic foot amputation was calculated via a local survey of the various private hospitals of Faisalabad. The indirect costs in terms of loss of productivity and disability costs, transport costs, rehabilitation costs were not included in this study. The data were evaluated by using SPSS Version 23. Results: A total of 85 patients were included in our study. The male to female ratio was 2.7 to 1. The mean direct treatment cost for minor amputation was PKR 46926.00 ± 11730.90 ($382.35 ± 95.58), and the mean direct treatment cost for major amputation was PKR 53720.00 ± 12401.24 ($437.71 ± 101.40). Out of 85 amputations, 63 (74%) were major amputations, and the remaining 22 (26%) were minor amputations. The total cost for 63 major amputations was PKR 3,384,360 ($27568.91) and for 22 minor amputation was PKR 1,032,372 ($8409.67). The net cost came out to be PKR 4,416,732 ($35978.59) for all the 85 cases being reported in a tertiary care hospital of Faisalabad for six months. Conclusion: Diabetic foot, a preventable complication of long-term diabetes mellitus, has an economic burden on the hospital budget, which, if adequately addressed via primary prevention programme, can yield not just economical but medical benefits as well.

Direct treatment cost of atrial fibrillation in the elderly American population: a Medicare perspective

2008 ◽  
Vol 11 (2) ◽  
pp. 281-298 ◽  
Author(s):  
Won Chan Lee ◽  
Gervasio A Lamas ◽  
Sanjeev Balu ◽  
James Spalding ◽  
Qin Wang ◽  
...  
Keyword(s):  
Atrial Fibrillation ◽  
Treatment Cost ◽  
The Elderly ◽  
American Population ◽  
Direct Treatment ◽  
Direct Treatment Cost

Direct treatment cost outcomes among patients with medial meniscus deficiency: results from a 24-month surveillance study

2020 ◽  
Vol 36 (3) ◽  
pp. 427-437
Author(s):  
Elliott B. Hershman ◽  
John L. Jarvis ◽  
Travis Mick ◽  
Kristina Dushaj ◽  
Jonathan J. Elsner
Keyword(s):  
Treatment Cost ◽  
Medial Meniscus ◽  
Surveillance Study ◽  
Direct Treatment ◽  
Direct Treatment Cost ◽  
Cost Outcomes

scholarly journals PSY10 ANNUAL HEALTH INSURANCE TREATMENT COST OF RHEUMATOID ARTHRITIS BASED ON ROUTINELY COLLECTED FINANCING DATA

2020 ◽  
Vol 23 ◽  
pp. S372
Author(s):  
I. Boncz ◽  
D. Endrei ◽  
R. Pónusz ◽  
A. Sebestyén ◽  
N. Németh ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Health Insurance ◽  
Treatment Cost

scholarly journals A rheumatoid arthritis okozta országos epidemiológiai és egészségbiztosítási betegségteher Magyarországon

2021 ◽  
Vol 162 (Supplement-1) ◽  
pp. 30-37
Author(s):  
Diána Elmer ◽  
Dóra Endrei ◽  
Andor Sebestyén ◽  
Tímea Csákvári ◽  
Noémi Németh ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Health Insurance ◽  
Treatment Cost ◽  
Age Groups ◽  
International Classification Of Diseases ◽  
Cost Driver ◽  
Insurance Fund ◽  
Main Diagnosis ◽  
Classification Of Diseases

Összefoglaló. Bevezetés: A rheumatoid arthritisszel kapcsolatos szolgáltatások igénybevétele nagy teher az egészségügyi rendszerek számára. Célkitűzés: Elemzésünk célja volt a rheumatoid arthritis okozta éves epidemiológiai és egészségbiztosítási betegségteher meghatározása Magyarországon. Adatok és módszerek: Az elemzésben felhasznált adatok a Nemzeti Egészségbiztosítási Alapkezelő (NEAK) finanszírozási adatbázisából származnak, és a 2018. évet fedik le. Meghatároztuk az éves betegszámokat, a prevalenciát 100 000 lakosra, továbbá az éves egészségbiztosítási kiadásokat korcsoportos és nemenkénti bontásban valamennyi egészségbiztosítási ellátás tekintetében. A rheumatoid arthritis kórképet fődiagnózisként a Betegségek Nemzetközi Osztályozása (BNO, 10. revízió) szerinti M0690-es kóddal azonosítottuk. Eredmények: Meghatározó betegforgalmat a gyógyszerek ártámogatása esetében találtunk: 7015 férfi, 23 696 nő, együtt 30 711 fő. A gyógyszer-ártámogatás betegforgalmi adatai alapján a 100 000 főre eső prevalencia férfiaknál 150,2 fő, nőknél 464,0 fő, együtt 314,1 fő volt. A rheumatoid arthritis kezelésére a NEAK 1,64 milliárd Ft-ot (6,07 millió USD, illetve 5,14 millió EUR) költött 2018-ban. A kiadások 19,3%-a férfiaknál, míg 80,7%-a nőknél jelenik meg. A gyógyszer-ártámogatás (az összes kiadás 42,8%-a), a járóbeteg-szakellátás (21,9%) és az aktívfekvőbeteg-szakellátás (12,4%) voltak a meghatározó költségelemek. Az egy betegre jutó átlagos éves egészségbiztosítási kiadás 53 375 Ft (198 USD/167 EUR) volt. Következtetés: A gyógyszerek ártámogatása bizonyult a fő költségtényezőnek. A rheumatoid arthritis előfordulási gyakorisága 3,1-szer magasabb a nők esetében a férfiakhoz képest. Orv Hetil. 2021; 162(Suppl 1): 30–37. Summary. Introduction: Utilisation of services related to the treatment of rheumatoid arthritis poses a great burden for healthcare systems. Objecive: Our aim was to determine the annual epidemiological disease burden and the health insurance treatment cost of rheumatoid arthritis in Hungary. Data and methods: Data were derived from the financial database of the National Health Insurance Fund Administration (NHIFA) of Hungary, for the year 2018. The data analysed included annual patient numbers and prevalence per 100 000 population and annual health insurance treatment costs calculated for age groups and sex according to all health insurance treatment categories. Patients with rheumatoid arthritis were identified as main diagnosis with the following code of the International Classification of Diseases, 10th revision: M0690. Results: We found a significant patient turnover in pharmaceutical reimbursement: 7015 men, 23 696 women, in total 30 711 patients. Based on patient numbers in pharmaceuticals, prevalence for 100 000 population among men was 150.2 patients, among women 464.0, in total 314.1 patients. In 2018, NHIFA spent 1.64 billion HUF (6.07 million USD, 5.14 million EUR) on the treatment of patients with rheumatoid arthritis. 19.3% of the costs was spent on the treatment of male, 80.7% on female patients. Pharmaceuticals (42.8% of the total expenditures), outpatient care (21.9%) and acute inpatient care (12.4%) were the main cost drivers. Average annual health insurance treatment cost per patient was 53 375 HUF (198 USD/167 EUR). Conclusion: Pharmaceutical reimbursement was the major cost driver. The prevalence of rheumatoid arthritis was by 3.1 higher in women compared to men. Orv Hetil. 2021; 162(Suppl 1): 30–37.

Sign in / Sign up

Export Citation Format

Share Document